Professional Documents
Culture Documents
Roberto Cilia1, MD; Salvatore Bonvegna1,*, MD; Giulia Straccia1,2,*, MD; Golfrè Andreasi Nico1,*, MD;
Antonio E. Elia1, MD, PhD; Luigi M. Romito1, MD, PhD; Grazia Devigili1, MD, PhD; Emanuele
Accepted Article
Cereda3, MD, PhD; Roberto Eleopra, 1 MD.
Corresponding author:
Roberto Cilia, MD
Fondazione IRCCS Istituto Neurologico Carlo Besta, Parkinson and Movement Disorders Unit, via
Celoria 11, 20133, Milan, Italy; Tel. (+39) 23942368; Fax (+39) 23942539; Email:
roberto.cilia@istituto-besta.it
Title character count: 98; Abstract word count: 150; Manuscript word count: 1700;
References: 31; Number of Tables and Figures: Tables 2
Financial disclosures/Conflict of interest RC has received fees for speaking at conferences from
Zambon, Bial, UCB, and Lusofarmaco; has received fees for consultancies from Roche, Z-Cube; has
received congress sponsorship from Zambon, and Boston Scientific. The other authors reported no
conflicts of interest.
Funding. This study was not funded.
This article has been accepted for publication and undergone full peer review but has not
been through the copyediting, typesetting, pagination and proofreading process which may
lead to differences between this version and the Version of Record. Please cite this article
as doi: 10.1002/mds.28170
Results
Demographic and clinical features at baseline were similar between PD cases and matched control
subjects, except for the greater need to increase dopaminergic therapy dosing and higher rate of contacts
with confirmed COVID-19 among cases (Table 1). COVID-19 symptoms were mild, managed at home
without symptomatic therapy in 3 cases (25%); 8 cases (66.7%) had moderate illness, pharmacologically
managed at home by the general practitioner; only one patient was hospitalized (8.3%) due to
pneumonia. COVID symptoms remitted in ten out of 12 (83.3%) cases and were still ongoing in two
patients (16.7%; both remitted at subsequent follow-up on May 15th); nobody died.
At within-group comparison, cases evidenced a significant worsening of the CISI-PD total and
motor-signs scores, MDS-UPDRS part-II score, the NMSS total score and the urinary domain sub-score
(Table 2, footnote d). Between-group case-control analysis additionally revealed greater motor
disability (at CISI-PD), motor fluctuations (at MDS-UPDRS part-IV), and nonmotor complaints.
Involvement of cognitive functions was marginal (no change at CISI-PD), and autonomic cardiovascular
and sexual functions remained unaffected (Table 2).
Finally, considering the greater rate of diarrhoea among COVID-19 cases (Table 1) and its
detrimental effect on the pharmacokinetics of dopaminergic medications (particularly levodopa), we
Discussion
To our knowledge, this is the first community-based case-control study describing the effects of
symptomatic COVID-19 on PD motor and nonmotor symptoms. First, PD patients who develop
symptomatic COVID-19 were neither older age nor with longer disease duration than those screening
negative, but rather had nonsignificant 3.5-year younger age and 2.0-year shorter disease duration. The
lack of case fatalities is consistent with the Italian case-fatality rate of 3.5% at 60-69 years of age.[15]
Similarly, only one patient (8.3%) needed to be admitted to hospital for severe COVID-19 illness, which
is in line with the frequency of hospitalization previously reported in general population of the
Lombardy region.[23] We expand previous report in advanced PD[12] and show that mild-to-moderate
COVID-19 may be contracted independently of age and PD duration and that PD patients with mid-
stage PD do not seem to have an overall worse outcome than non-PD population.[15] Concerning the
primary objective of the study, we found a worsening of motor and nonmotor symptoms of PD in the
COVID-19 group compared to matched control subjects over the study period.
Motor symptoms. COVID-19 induced a significant worsening of motor performance, motor-
related disability and experiences of daily living. Worsening of levodopa-responsive motor symptoms
and increased daily OFF-time, caused either by the effects of acute systemic inflammatory response[6-
9] or by changes in pharmacokinetics, was so pronounced in one-third of cases to prompt neurologists to
increase dopaminergic therapy. We explored the relative contribution of suboptimal absorption of oral
therapy by adjusting motor endpoints for diarrhoea, which was present in 50% of cases. According to
multivariate analysis, concomitant diarrhoea explained the increase in motor fluctuations, but could not
entirely explain the worsening of motor disability and motor aspects of experiences of daily living.
Nonmotor symptoms. COVID-19 significant aggravated a number of nonmotor symptoms. Increased
fatigue in our cohort was fully explained by COVID-19, confirming that it a common COVID-19
symptom[24], as described in PD following systemic inflammation.[25] Urinary urge/incontinence and
nicturia were explained by the infection as well as increased motor fluctuations, which were partly due
Conclusions
PD patients may experience substantial worsening of motor and nonmotor symptoms during mild-to-
moderate COVID-19 illness, independently of age and disease duration. Clinicians should take
pharmacokinetic changes into consideration before adjusting therapy regimen (e.g., management of
dehydration secondary to fever, diarrhoea, anorexia with reduced water intake). Although we speculate
that subacute clinical changes in PD associated to nonsevere COVID-19 illness are likely caused by
systemic inflammatory response[8-9] rather than a direct invasion of the central nervous system,[27,28]
further studies in larger PD populations are warranted to clarify the cause-effect relationship among
clinical changes and the severity of COVID-19 illness, cytokine levels and virus detection in the
cerebrospinal fluid.
Acknowledgments. We are thankful to Francesca De Giorgi for providing the dataset of patients with
parkinsonism resident visited at the Besta Institute.
References
[1] Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns
Hopkins. Updated May 7, 2020. Accessed May 7, 2020.
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
[2] Stoessl AJ, Bhatia KP, Merello M. Editorial: movement disorders in the world of COVID-19. Mov Disord
2020 Apr 6. [Epub ahead of print].
[3] Papa SM, Brundin P, Fung VSC, et al; and the MDS-Scientific Issues Committee. Impact of the COVID-19
Pandemic on Parkinson's Disease and Movement Disorders. Mov Disord. 2020 Apr 6. [Epub ahead of print]
[4] Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and
emerging opportunities. J Parkinsons Dis 2020; 10(2):351–354.
[5] Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B,
Rodríguez-Perez AI. Dopamine-angiotensin interactions in the basal ganglia and their relevance for
Parkinson's disease. Mov Disord 2013; 28(10):1337-42.
[6] Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with
Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One 2012; 7(10):e47387.
[7] Green HF, Khosousi S, Svenningsson P. Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-
Motor Symptoms in Parkinson's Disease. J Parkinsons Dis 2019; 9(4):705-709.
[8] Brugger F, Erro R, Balint B, Kägi G, Barone P, Bhatia KP. Why is there motor deterioration in Parkinson's
disease during systemic infections-a hypothetical view. NPJ Parkinsons Dis 2015; 1:15014.
[9] Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, Sugiyama H, Sawada H. Delirium and high
fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study.
PLoS One. 2014; 9(6):e94944.
[10] Vijayan S, Singh B, Ghosh S, Stell R, Mastaglia FL. Brainstem ventilator dysfunction: A plausible
mechanism for dyspnea in Parkinson's Disease? Mov Disord. 2020; 35(3):379-388.
[11] Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson's Disease. Int Rev Neurobiol
2017; 132:33-54.
[12] Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease patients affected by COVID-19.
Mov Disord 2020 Apr 29. [Epub ahead of print]
[13] Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS Clinical Diagnostic Criteria
for Parkinson’s Disease. Mov Disord 2015; 30: 1591-1600.
Abbreviations: COPD, Chronic obstructive pulmonary disease, including asthma; DA, dopamine agonists; iCOMT,
catechol-O-methyltransferase inhibitors; ICU, intensive care unit; iMAO-B, Monoamine Oxidase type B
Inhibitors; LEDD, levodopa equivalent daily dose; PD, Parkinson’s disease; Pts, patients.
Data are shown as number of patients (N) and frequency (%) or as mean (standard deviation).
a
These data refer to the baseline state (January 2020) before the COVID outbreak in Italy
b
One case was on Levodopa/Carbidopa gel infusion; one control was on subthalamic nucleus stimulation.
c
Defined according to the WHO criteria.[14]
d
Including daily intake of drugs targeting rheumatic diseases or malignancies (e.g., steroids,
hydroxychloroquine, methotrexate, azathioprine, etc.) prior to the baseline assessment.
e
One patient with meningioma among cases, 4 patients with chronic cerebrovascular disease among controls.
f
Between-group comparisons of continuous variables were performed using the unpaired Student’s t-test, while
categorical variables were analyzed by the Fisher’s exact test.
Between-
Baseline End of Baseline End of group P-
Variable a Change b Change b
study a a
study a difference in value c
change b,c
a) CISI-PD
7.4 1.3 (0.3, 7.6 0.1 (0.0, <0.001
Total score 6.2 (4.1) 7.5 (4.7) 1.2 (0.6, 1.7)
2.2) d
Accepted Article
(4.1) (4.8) 0.2)
3.0 0.7 (0.2, 2.7 0.0 (- <0.001
Motor signs 2.3 (1.4) 2.7 (1.4) 0.6 (0.3, 0.9)
(1.3) 1.2) d (1.4) 0.0, 0.1)
2.4 0.3 (-0.1, 2.4 0.0 (0.0, 0.003
Disability 2.1 (1.1) 2.4 (1.4) 0.3 (0.1, 0.5)
(1.4) 0.7) (1.4) 0.0)
Motor 0.7 0.1 (-0.1, 1.0 0.0 (- 0.42
0.6 (1.2) 1.0 (1.4) 0.1 (-0.1, 0.2)
complications (1.4) 0.3) (1.4) 0.1, 0.1)
1.3 0.1 (-0.1, 1.5 0.0 (- 0.089
Cognitive status 1.2 (1.2) 1.5 (1.5) 0.1 (-0.0, 0.3)
(1.2) 0.4) (1.5) 0.1, 0.1)
b) MDS-UPDRS
11.9 13.7 1.8 (0.4, 12.0 12.2 0.2 (0.0, <0.001
UPDRS part II 1.6 (0.8, 2.3)
(7.6) (9.4) 3.1) d (8.3) (8.3) 0.4) d
4.2 1.2 (-0.2, 4.8 0.0 (0.0, 0.002
UPDRS part IV 3.0 (6.2) 4.8 (6.6) 1.2 (0.5, 2.9)
(8.1) 2.5) (6.6) 0.0)
UPDRS part IV - 1.5 0.4 (-0.2, 1.7 0.0 (0.0, 0.014
1.1 (2.0) 1.7 (2.5) 0.4 (0.1, 0.7)
OFF e (2.8) 1.0) (2.5) 0.0)
UPDRS part IV – 0.5 0.2 (-0.2, 0.6 0.0 (0.0, 0.083
0.3 (1.2) 0.6 (1.2) 0.2 (-0.0, 0.4)
DYSK e (1.7) 0.5) (1.2) 0.0)
c) NMSS
10.4 41.9 41.8 <0.001
39.3 49.7 -0.1 (- 10.5 (5.2,
Total score (0.2, (40.8) (41.1)
(28.1) (43.1) 0.7, 0.5) 15.9)
20.6) d
-0.4 (- 0.13
1.8 0.3 (-1.1, 0.9
Cardiovascular 1.5 (1.3) 1.3 (2.3) 0.6, - 0.6 (-0.2, 1.4)
(3.3) 1.6) (1.9)
0.2) d
10.5 2.2 (-0.2, 10.0 9.8 -0.1 (- 0.001
Sleep/Fatigue 8.3 (6.4) 2.3 (1.0, 3.6)
(7.1) 4.6) (9.7) (9.7) 0.4, 0.1)
8.6 11.8 3.2 (-1.2, 7.6 7.6 0.0 (- 0.010
Mood/Apathy 3.1 (0.8, 5.5)
(14.3) (17.9) 7.5) (11.0) (11.3) 0.4, 0.4)
Perceptual 0.9 0.0 (0.0, 0.7 0.0 (0.0, 1.00
0.9 (1.6) 0.7 (1.6) 0.0 (0.0, 0.0)
problems (1.6) 0.0) (1.6) 0.0)
4.7 1.5 (-1.1, 4.9 0.0 (- 0.038
3.2 (4.1) 4.9 (7.1) 1.4 (0.1, 2.8)
Attention/memory (7.8) 4.1) (7.1) 0.1, 0.2)
3.2 -0.1 (- 3.2 0.2 (- 0.17
Gastrointestinal f 3.3 (5.1) 3.0 (3.8) -0.4 (-0.9, 0.2)
(5.2) 0.8, 0.5) (3.9) 0.0, 0.4)
10.8 2.2 (0.1, 8.3 0.0 (0.0, <0.001
Urinary 8.6 (7.5) 8.3 (9.0) 2.3 (1.1, 3.4)
(9.3) 4.4) d (9.0) 0.0)
1.3 0.0 (0.0, 2.1 0.0 (0.0, 1.00
Sexual function 1.3 (2.0) 2.1 (4.5) 0.0 (0.0, 0.0)
(2.0) 0.0) (4.5) 0.0)
4.8 1.3 (-0.5, 4.3 0.1 (- 0.014
Miscellaneous 3.5 (3.3) 4.2 (5.9) 1.2 (0.2, 2.1)
(3.7) 3.0) (5.9) 0.0, 0.2)
Abbreviations: CISI-PD, Clinical Impression of Severity Index for Parkinson’s Disease. MDS-UPDRS, Movement Disorders
Society Unified PD Rating Scale; NMSS, non-motor symptoms scale.
a
Data are provided as mean (standard deviation)